Literature DB >> 17602691

Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistance.

Sonja C Bernhard1, Barbara Nerima, Pascal Mäser, Reto Brun.   

Abstract

Resistance to melarsoprol and pentamidine was induced in bloodstream-form Trypanosoma brucei rhodesiense STIB 900 in vitro, and drug sensitivity was determined for melarsoprol, pentamidine and furamidine. The resistant populations were also inoculated into immunosuppressed mice to verify infectivity and to monitor whether rodent passage selects for clones with altered drug sensitivity. After proliferation in the mouse, trypanosomes were isolated and their IC(50) values to the three drugs were determined. To assess the stability of drug-induced resistance, drug pressure was ceased for 2 months and the drug sensitivity was determined again. Resistance was stable, with a few exceptions that are discussed. Drug IC(50)s indicated cross-resistance among all drugs, but to varying extents: resistance of the melarsoprol-selected and pentamidine-selected trypanosomes to pentamidine was the same, but the pentamidine-selected trypanosome population showed lower resistance to melarsoprol than the melarsoprol-selected trypanosomes. Interestingly, both resistant populations revealed the same intermediate cross-resistance to furamidine. Resistant trypanosome populations were characterised by molecular means, referring to the status of the TbAT1 gene. The melarsoprol-selected population apparently had lost TbAT1, whereas in the pentamidine-selected trypanosome population it was still present.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602691     DOI: 10.1016/j.ijpara.2007.05.007

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  17 in total

1.  In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.

Authors:  Tanja Wenzler; Sihyung Yang; Donald A Patrick; Olivier Braissant; Mohamed A Ismail; Richard R Tidwell; David W Boykin; Michael Zhuo Wang; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

2.  Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.

Authors:  Marcel Kaiser; Michael A Bray; Monica Cal; Bernadette Bourdin Trunz; Els Torreele; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

3.  Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.

Authors:  Tanja Wenzler; Sihyung Yang; Olivier Braissant; David W Boykin; Reto Brun; Michael Zhuo Wang
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

4.  In vitro and in vivo activities of 2-aminopyrazines and 2-aminopyridines in experimental models of human African trypanosomiasis.

Authors:  Suman K Vodnala; Thomas Lundbäck; Birger Sjöberg; Richard Svensson; Martin E Rottenberg; Lars G J Hammarström
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

5.  Diverse effects on mitochondrial and nuclear functions elicited by drugs and genetic knockdowns in bloodstream stage Trypanosoma brucei.

Authors:  Christal Worthen; Bryan C Jensen; Marilyn Parsons
Journal:  PLoS Negl Trop Dis       Date:  2010-05-04

6.  New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.

Authors:  Tanja Wenzler; David W Boykin; Mohamed A Ismail; James Edwin Hall; Richard R Tidwell; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

7.  Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis.

Authors:  Juan D Unciti-Broceta; José L Arias; José Maceira; Miguel Soriano; Matilde Ortiz-González; José Hernández-Quero; Manuel Muñóz-Torres; Harry P de Koning; Stefan Magez; José A Garcia-Salcedo
Journal:  PLoS Pathog       Date:  2015-06-25       Impact factor: 6.823

8.  Genotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawal.

Authors:  Anne J N Kazibwe; Barbara Nerima; Harry P de Koning; Pascal Mäser; Michael P Barrett; Enock Matovu
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29

Review 9.  Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.

Authors:  Nicola Baker; Harry P de Koning; Pascal Mäser; David Horn
Journal:  Trends Parasitol       Date:  2013-01-30

Review 10.  Drug repurposing and human parasitic protozoan diseases.

Authors:  Katherine T Andrews; Gillian Fisher; Tina S Skinner-Adams
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-03-24       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.